BioWorld Asia

March 2, 2005

View Archived Issues

Vernalis Getting £30M With Plans To Build Sales Force

Novel Monoclonal Technology Might Bring Raft Of Therapies

With Partner Re-Evaluating, Phytopharm Pulls Funding

Stirling Medical Solutions Gets Funding From ITI, IMI

Opsona Raises EUR6.25M For Anti-Inflammatory Products

Other News To Note

Biogen Idec, Elan Plummet On Withdrawal Of Tysabri

Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...